Which has better earnings & valuation, BIIB or TGTX?

Biogen has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Biogen $9.89B 3.24 $1.29B $5.65 38.43 TG Therapeutics $616.29M 13.38 $447.18M $2.74 19.67

Is BIIB or TGTX more profitable?

TG Therapeutics has a net margin of 55.22% compared to Biogen's net margin of 8.32%. TG Therapeutics' return on equity of 73.49% beat Biogen's return on equity. Company Net Margins Return on Equity Return on Assets Biogen 8.32% 11.18% 6.88% TG Therapeutics 55.22% 73.49% 34.14%

Does the media refer more to BIIB or TGTX?

In the previous week, Biogen had 2 more articles in the media than TG Therapeutics. MarketBeat recorded 11 mentions for Biogen and 9 mentions for TG Therapeutics. Biogen's average media sentiment score of 1.10 beat TG Therapeutics' score of 0.92 indicating that Biogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 7 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, TGTX or INSM?

TG Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TG Therapeutics $616.29M 13.38 $447.18M $2.74 19.67 Insmed $1.14B 24.84 -$1.28B -$4.11 N/A

Is TGTX or INSM more profitable?

TG Therapeutics has a net margin of 55.22% compared to Insmed's net margin of -76.94%. TG Therapeutics' return on equity of 73.49% beat Insmed's return on equity. Company Net Margins Return on Equity Return on Assets TG Therapeutics 55.22% 73.49% 34.14% Insmed -76.94% -123.94% -44.30%

Does the media prefer TGTX or INSM?

In the previous week, Insmed had 2 more articles in the media than TG Therapeutics. MarketBeat recorded 11 mentions for Insmed and 9 mentions for TG Therapeutics. Insmed's average media sentiment score of 1.15 beat TG Therapeutics' score of 0.92 indicating that Insmed is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Insmed 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer TGTX or BNTX?

In the previous week, BioNTech had 12 more articles in the media than TG Therapeutics. MarketBeat recorded 21 mentions for BioNTech and 9 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.92 beat BioNTech's score of 0.44 indicating that TG Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 10 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings and valuation, INCY or TGTX?

Incyte has higher revenue and earnings than TG Therapeutics. Incyte is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Incyte $5.82B 4.23 $1.29B $7.85 15.47 TG Therapeutics $616.29M 13.38 $447.18M $2.74 19.67

Is INCY or TGTX more profitable?

TG Therapeutics has a net margin of 55.22% compared to Incyte's net margin of 27.71%. TG Therapeutics' return on equity of 73.49% beat Incyte's return on equity. Company Net Margins Return on Equity Return on Assets Incyte 27.71% 29.93% 22.88% TG Therapeutics 55.22% 73.49% 34.14%

Does the media refer more to INCY or TGTX?

In the previous week, Incyte had 10 more articles in the media than TG Therapeutics. MarketBeat recorded 19 mentions for Incyte and 9 mentions for TG Therapeutics. Incyte's average media sentiment score of 0.98 beat TG Therapeutics' score of 0.92 indicating that Incyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 9 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, ROIV or TGTX?

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Roivant Sciences $7.53M 3,914.66 -$299.77M -$0.53 N/A TG Therapeutics $616.29M 13.38 $447.18M $2.74 19.67

Does the media refer more to ROIV or TGTX?

In the previous week, Roivant Sciences had 32 more articles in the media than TG Therapeutics. MarketBeat recorded 41 mentions for Roivant Sciences and 9 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.92 beat Roivant Sciences' score of 0.62 indicating that TG Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 13 Very Positive mention(s) 8 Positive mention(s) 16 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

TG Therapeutics (TGTX) Competitors

$53.89 -1.50 (-2.71%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$53.86 -0.02 (-0.05%)

As of 09/11/2026 07:30 PM Eastern

Compare

TGTX vs. BIIB, INSM, BNTX, INCY, and ROIV

Should you buy TG Therapeutics stock or one of its competitors? TG Therapeutics's main competitors and comparable companies include Biogen (BIIB), Insmed (INSM), BioNTech (BNTX), Incyte (INCY), and Roivant Sciences (ROIV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TG Therapeutics compare to Biogen?

Biogen (NASDAQ:BIIB) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, media sentiment, risk, dividends, analyst recommendations, earnings and profitability.

Biogen has higher revenue and earnings than TG Therapeutics. TG Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biogen	$9.89B	3.24	$1.29B	$5.65	38.43
TG Therapeutics	$616.29M	13.38	$447.18M	$2.74	19.67

Biogen currently has a consensus target price of $230.14, indicating a potential upside of 5.98%. TG Therapeutics has a consensus target price of $63.00, indicating a potential upside of 16.90%. Given TG Therapeutics' higher probable upside, analysts clearly believe TG Therapeutics is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

87.9% of Biogen shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 0.3% of Biogen shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Biogen had 2 more articles in the media than TG Therapeutics. MarketBeat recorded 11 mentions for Biogen and 9 mentions for TG Therapeutics. Biogen's average media sentiment score of 1.10 beat TG Therapeutics' score of 0.92 indicating that Biogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Biogen	7 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 55.22% compared to Biogen's net margin of 8.32%. TG Therapeutics' return on equity of 73.49% beat Biogen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biogen	8.32%	11.18%	6.88%
TG Therapeutics	55.22%	73.49%	34.14%

Biogen has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.67, meaning that its stock price is 67% more volatile than the broader market.

Summary

Biogen beats TG Therapeutics on 10 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Insmed?

TG Therapeutics (NASDAQ:TGTX) and Insmed (NASDAQ:INSM) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

58.6% of TG Therapeutics shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 2.1% of Insmed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Insmed had 2 more articles in the media than TG Therapeutics. MarketBeat recorded 11 mentions for Insmed and 9 mentions for TG Therapeutics. Insmed's average media sentiment score of 1.15 beat TG Therapeutics' score of 0.92 indicating that Insmed is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Insmed	8 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 55.22% compared to Insmed's net margin of -76.94%. TG Therapeutics' return on equity of 73.49% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
Insmed	-76.94%	-123.94%	-44.30%

TG Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market. Comparatively, Insmed has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

TG Therapeutics has higher earnings, but lower revenue than Insmed. Insmed is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.38	$447.18M	$2.74	19.67
Insmed	$1.14B	24.84	-$1.28B	-$4.11	N/A

TG Therapeutics currently has a consensus target price of $63.00, suggesting a potential upside of 16.90%. Insmed has a consensus target price of $205.52, suggesting a potential upside of 58.81%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

TG Therapeutics beats Insmed on 9 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to BioNTech?

TG Therapeutics (NASDAQ:TGTX) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

TG Therapeutics has higher earnings, but lower revenue than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TG Therapeutics	$616.29M	13.38	$447.18M	$2.74	19.67
BioNTech	$2.65B	9.23	-$1.29B	-$7.83	N/A

In the previous week, BioNTech had 12 more articles in the media than TG Therapeutics. MarketBeat recorded 21 mentions for BioNTech and 9 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.92 beat BioNTech's score of 0.44 indicating that TG Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	10 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

58.6% of TG Therapeutics shares are held by institutional investors. Comparatively, 15.5% of BioNTech shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 19.2% of BioNTech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

TG Therapeutics has a net margin of 55.22% compared to BioNTech's net margin of -63.54%. TG Therapeutics' return on equity of 73.49% beat BioNTech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TG Therapeutics	55.22%	73.49%	34.14%
BioNTech	-63.54%	-6.86%	-6.00%

TG Therapeutics presently has a consensus target price of $63.00, suggesting a potential upside of 16.90%. BioNTech has a consensus target price of $126.00, suggesting a potential upside of 30.26%. Given BioNTech's stronger consensus rating and higher probable upside, analysts plainly believe BioNTech is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

TG Therapeutics has a beta of 1.67, suggesting that its stock price is 67% more volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, suggesting that its stock price is 29% more volatile than the broader market.

Summary

TG Therapeutics beats BioNTech on 10 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Incyte has higher revenue and earnings than TG Therapeutics. Incyte is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.82B	4.23	$1.29B	$7.85	15.47
TG Therapeutics	$616.29M	13.38	$447.18M	$2.74	19.67

97.0% of Incyte shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 16.2% of Incyte shares are owned by company insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Incyte currently has a consensus price target of $124.05, suggesting a potential upside of 2.12%. TG Therapeutics has a consensus price target of $63.00, suggesting a potential upside of 16.90%. Given TG Therapeutics' higher possible upside, analysts clearly believe TG Therapeutics is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Incyte had 10 more articles in the media than TG Therapeutics. MarketBeat recorded 19 mentions for Incyte and 9 mentions for TG Therapeutics. Incyte's average media sentiment score of 0.98 beat TG Therapeutics' score of 0.92 indicating that Incyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	9 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.67, meaning that its share price is 67% more volatile than the broader market.

TG Therapeutics has a net margin of 55.22% compared to Incyte's net margin of 27.71%. TG Therapeutics' return on equity of 73.49% beat Incyte's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
TG Therapeutics	55.22%	73.49%	34.14%

Summary

Incyte beats TG Therapeutics on 10 of the 17 factors compared between the two stocks.

How does TG Therapeutics compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and TG Therapeutics (NASDAQ:TGTX) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

TG Therapeutics has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$7.53M	3,914.66	-$299.77M	-$0.53	N/A
TG Therapeutics	$616.29M	13.38	$447.18M	$2.74	19.67

Roivant Sciences has a beta of 1.12, indicating that its stock price is 12% more volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.67, indicating that its stock price is 67% more volatile than the broader market.

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 58.6% of TG Therapeutics shares are owned by institutional investors. 8.8% of Roivant Sciences shares are owned by insiders. Comparatively, 8.9% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Roivant Sciences had 32 more articles in the media than TG Therapeutics. MarketBeat recorded 41 mentions for Roivant Sciences and 9 mentions for TG Therapeutics. TG Therapeutics' average media sentiment score of 0.92 beat Roivant Sciences' score of 0.62 indicating that TG Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	13 Very Positive mention(s)	8 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has a net margin of 55.22% compared to Roivant Sciences' net margin of -3,534.96%. TG Therapeutics' return on equity of 73.49% beat Roivant Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,534.96%	-22.94%	-21.53%
TG Therapeutics	55.22%	73.49%	34.14%

Roivant Sciences presently has a consensus target price of $40.63, suggesting a potential downside of 0.48%. TG Therapeutics has a consensus target price of $63.00, suggesting a potential upside of 16.90%. Given TG Therapeutics' higher possible upside, analysts plainly believe TG Therapeutics is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85
TG Therapeutics	2 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

TG Therapeutics beats Roivant Sciences on 11 of the 17 factors compared between the two stocks.

Get TG Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TGTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TGTX vs. The Competition

Export

Metric	TG Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.48B	$3.86B	$7.16B	$12.73B
Dividend Yield	N/A	3.63%	2.56%	11.15%
P/E Ratio	19.67	14.18	274.10	25.29
Price / Sales	13.38	1,482.03	656.00	99.06
Price / Cash	19.77	106.68	77.04	51.44
Price / Book	13.21	15.12	10.33	6.20
Net Income	$447.18M	-$22.86M	$3.50B	$358.50M
7 Day Performance	-3.75%	-4.35%	-3.35%	-2.35%
1 Month Performance	8.87%	-0.04%	-0.43%	-2.77%
1 Year Performance	67.57%	40.63%	19.21%	7.63%

TG Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TGTX TG Therapeutics	3.3939 of 5 stars	$53.89 -2.7%	$63.00 +16.9%	+66.0%	$8.48B	$616.29M	19.67	399
BIIB Biogen	3.2673 of 5 stars	$220.83 flat	$228.50 +3.5%	+45.9%	$32.63B	$9.89B	39.08	7,500	Positive News Analyst Forecast
INSM Insmed	3.4202 of 5 stars	$126.29 flat	$205.52 +62.7%	-11.2%	$27.58B	$606.42M	N/A	1,664	News Coverage Positive News Insider Trade
BNTX BioNTech	4.2591 of 5 stars	$103.76 flat	$127.44 +22.8%	-7.3%	$26.24B	$3.25B	N/A	7,807	Analyst Downgrade Insider Trade
INCY Incyte	3.4983 of 5 stars	$126.75 flat	$124.05 -2.1%	+41.0%	$25.69B	$5.14B	16.15	2,844	News Coverage Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TGTX) was last updated on 9/12/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TG Therapeutics (TGTX) Competitors

TGTX vs. BIIB, INSM, BNTX, INCY, and ROIV

How does TG Therapeutics compare to Biogen?

Summary

How does TG Therapeutics compare to Insmed?

Summary

How does TG Therapeutics compare to BioNTech?

Summary

How does TG Therapeutics compare to Incyte?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TG Therapeutics (TGTX) Competitors

TGTX vs. BIIB, INSM, BNTX, INCY, and ROIV

How does TG Therapeutics compare to Biogen?

Which has better earnings & valuation, BIIB or TGTX?

Do analysts recommend BIIB or TGTX?

Do insiders & institutionals have more ownership in BIIB or TGTX?

Does the media refer more to BIIB or TGTX?

Is BIIB or TGTX more profitable?

Which has more risk and volatility, BIIB or TGTX?

Summary

How does TG Therapeutics compare to Insmed?

Do insiders and institutionals have more ownership in TGTX or INSM?

Does the media prefer TGTX or INSM?

Is TGTX or INSM more profitable?

Which has more risk & volatility, TGTX or INSM?

Which has better earnings & valuation, TGTX or INSM?

Do analysts prefer TGTX or INSM?

Summary

How does TG Therapeutics compare to BioNTech?

Which has higher earnings and valuation, TGTX or BNTX?

Does the media prefer TGTX or BNTX?

Do insiders & institutionals hold more shares of TGTX or BNTX?

Is TGTX or BNTX more profitable?

Do analysts rate TGTX or BNTX?

Which has more risk & volatility, TGTX or BNTX?

Summary

How does TG Therapeutics compare to Incyte?

Which has higher earnings and valuation, INCY or TGTX?

Do insiders and institutionals hold more shares of INCY or TGTX?

Do analysts recommend INCY or TGTX?

Does the media refer more to INCY or TGTX?

Which has more risk and volatility, INCY or TGTX?

Is INCY or TGTX more profitable?

Summary

How does TG Therapeutics compare to Roivant Sciences?

Which has preferable valuation and earnings, ROIV or TGTX?

Which has more volatility and risk, ROIV or TGTX?

Do insiders & institutionals hold more shares of ROIV or TGTX?

Does the media refer more to ROIV or TGTX?

Is ROIV or TGTX more profitable?

Do analysts recommend ROIV or TGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TGTX vs. The Competition

TG Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools